Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The response of cancers to BRAF inhibition underscores the importance of cancer systems biology.

Science signaling - 16 Oct 2012

Stites Edward C

Abstract excerpt

The BRAF inhibitor vemurafenib has become an important treatment option for melanoma patients, the majority of whom have a BRAF(V600E) mutation driving their malignancy. However, this same agent does not generally benefit colon cancer patients who have the BRAF(V600E) mutation. Recent work sugges...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials as Topic
Share to Colonic Neoplasms
Share to Drug Screening Assays, Antitumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indoles

Share to Melanoma

Share to Sulfonamides

Share to Systems Biology

Share to Vemurafenib

Source

Identifiers

PMID: 23074264
DOI: 10.1126/scisignal.2003354

Genes

BRAF
EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23074264-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

The response of cancers to BRAF inhibition underscores the importance of cancer systems biology.PMID 23074264Read ↗

Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanomaSemantic proximity Read ↗

Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanomaSemantic proximity Read ↗

EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of <i>BRAF</i> -Mutant Colorectal Cancers to RAF Inhibition with VemurafenibSemantic proximity Read ↗

Clinical responses to ERK inhibition in BRAF V600E-mutant colorectal cancer predicted using a computational modelSemantic proximity Read ↗

Response to BRAF-targeted Therapy Is Enhanced by Cotargeting VEGFRs or WNT/β-Catenin Signaling in BRAF-mutant Colorectal Cancer Models.Semantic proximity Read ↗

Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.Semantic proximity Read ↗

Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406).Semantic proximity Read ↗

Targeting of super-enhancers and mutant BRAF can suppress growth of BRAF-mutant colon cancer cells via repression of MAPK signaling pathway.Semantic proximity Read ↗

BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.